Company profile for ORIC Pharmaceuticals

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

ORIC was established in 2014 with a bold vision of Overcoming Resistance in Cancer. Resistance limits the efficacy of otherwise significant cancer treatment breakthroughs, regardless of modality. Our ambition at ORIC is to discover and develop innovative therapies that benefit patients with cancer, including by making existing therapies more effective for a longer period of time. Our initial project was a small molecule antago...
ORIC was established in 2014 with a bold vision of Overcoming Resistance in Cancer. Resistance limits the efficacy of otherwise significant cancer treatment breakthroughs, regardless of modality. Our ambition at ORIC is to discover and develop innovative therapies that benefit patients with cancer, including by making existing therapies more effective for a longer period of time. Our initial project was a small molecule antagonist of the glucocorticoid receptor (GR), which has been implicated in resistance to various treatment modalities—including chemotherapy, immunotherapy, and anti-hormonal therapy—and across multiple cancers.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
U.S.A
Address
Address
240 E. Grand Ave, 2nd Floor South San Francisco, CA 94080
Telephone
Telephone
(650) 388-5600
Linkedin
Linkedin
youtube
YouTube
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Default Event

DDL Conference

Not Confirmed

envelop Contact Supplier

DDL Conference

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.globenewswire.com/news-release/2025/12/05/3200990/0/en/ORIC-Pharmaceuticals-Reports-Inducement-Grants-under-Nasdaq-Listing-Rule-5635-c-4.html

GLOBENEWSWIRE
05 Dec 2025

https://www.globenewswire.com/news-release/2025/12/06/3201024/0/en/ORIC-Pharmaceuticals-Presents-Potential-Best-in-Class-Profile-for-Enozertinib-with-Robust-Systemic-and-CNS-Activity-in-1L-and-2L-NSCLC-Patients-with-EGFR-Exon-20-Mutations-at-the-E.html

GLOBENEWSWIRE
05 Dec 2025

https://www.globenewswire.com/news-release/2025/12/03/3199316/0/en/ORIC-Pharmaceuticals-Announces-Enozertinib-ORIC-114-Late-Breaking-Oral-Presentations-in-EGFR-Atypical-and-EGFR-exon-20-NSCLC-at-the-ESMO-Asia-Congress-2025.html

GLOBENEWSWIRE
03 Dec 2025

https://www.globenewswire.com/news-release/2025/12/01/3196976/0/en/ORIC-Pharmaceuticals-Announces-Enozertinib-ORIC-114-Poster-Presentation-in-HER2-exon-20-NSCLC-at-the-ESMO-Asia-Congress-2025.html

GLOBENEWSWIRE
01 Dec 2025

https://www.globenewswire.com/news-release/2025/11/24/3193927/0/en/ORIC-Pharmaceuticals-to-Participate-in-the-8th-Annual-Evercore-Healthcare-Conference.html

GLOBENEWSWIRE
24 Nov 2025

https://www.globenewswire.com/news-release/2025/11/13/3187843/0/en/ORIC-Pharmaceuticals-Announces-Completion-of-Dose-Exploration-Portion-of-ORIC-944-Phase-1b-Clinical-Trial-and-Continues-to-Demonstrate-Potential-Best-in-Class-Efficacy-and-Safety.html

GLOBENEWSWIRE
13 Nov 2025

REF. STANDARDS & IMPURITIES

Upload your portfolio for free, ask us

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty